靶向胰高血糖素样肽-1/胰高血糖素/葡萄糖依赖性促胰岛素多肽受体的肥胖症新型治疗药物——retatrutide
A novel obesity treatment drug targeting glucagon-like peptide-1/glucagon/glucose-dependent insulinotropic polypeptide receptor:retatrutide
王文轩 1冯东梅 1程卯生 1刘洋1
作者信息
- 1. 沈阳药科大学 制药工程学院 基于靶点的药物设计与研究教育部重点实验室,沈阳 110016
- 折叠
摘要
肥胖症是一种由遗传、环境等因素引起的以脂肪过多为特征的复杂疾病.retatrutide(研发代号:LY3437943)作为一种胰高血糖素样肽-1/胰高血糖素/葡萄糖依赖性促胰岛素多肽受体激动剂,在肥胖症及心血管疾病治疗中显示出长期有效性.Ⅰ、Ⅱ期临床试验结果表明,retatrutide具有良好的有效性和安全性.该药物目前正在处于Ⅲ期临床试验的招募阶段.本文主要对该药物的基本信息、作用机制、临床前研究及临床研究等方面进行概述.
Abstract
Obesity is a complex disease characterized by excess adiposity caused by genetic and environmental factors.As a glucagon-like peptide-1 receptor/glucagon/glucose-dependent insulinotropic polypeptide receptor agonist,retatrutide(research code:LY3437943)has demonstrated long-term efficacy in the treatments of obesity and cardiovascular disease.The results of phase Ⅰ and Ⅱ clinical trials showed that retatrutide had good efficacy and safety profiles.This drug is currently in the recruit-ment phase of phase Ⅲ clinical trials.This article provides an overview of the retatrutide's basic information,mechanism of ac-tion,pre-clinical studies and clinical studies.
关键词
retatrutide/肥胖症/2型糖尿病/奥利司他Key words
retatrutide/obesity/type 2 diabetes mellitus/orlistat引用本文复制引用
出版年
2024
NETL
NSTL
万方数据